Nightstar Therapeutics will be acquired by Biogen for a price of $25.50 per share, or nearly $877 million, the companies announced.
The agreement is conditional on approval from Nightstar shareholders and is expected to become effective by mid-year, according to a Nightstar press release.
“Ophthalmology is an emerging growth area for Biogen, and we are excited about the opportunity to work with the talented employees at Nightstar to advance potentially transformative gene therapy programs for rare retinal diseases,” Biogen CEO Michel Vounatsos said in a Biogen press release.
Uncategorized